跳到正文
MarketHOT
English
摘要
SEC · EDGAR 财务披露·· 12 天前精选AI 评分74

American Vanguard截至2026年9月30日第三季度及前九个月净亏损扩大,披露贷款契约合规风险

AMERICAN VANGUARD CORP (0000005981) (Filer)

AI 导读

American Vanguard截至2026年9月30日的第三季度净销售额为1.084亿美元,同比下降9.2%,净亏损1,767万美元;前九个月净销售额为3.487亿美元,同比下降4.3%,净亏损3,168万美元。

推荐理由

材料节选显示,公司九个月净亏损扩大且利息费用上升,并披露第一留置权贷款契约合规取决于第四季度实现显著调整后EBITDA。

正文

n

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2026

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

FOR THE TRANSITION PERIOD FROM TO

Commission file number 001-13795

AMERICAN VANGUARD CORPORATION

Delaware

95-2588080

(State or other jurisdiction of

Incorporation or organization)

(I.R.S. Employer

Identification Number)

15440 Laguna Canyon Road, Irvine, California

92618

(Address of principal executive offices)

(Zip Code)

(949) 260-1200

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading

Symbol(s)

Name of each exchange on which registered

Common Stock, $0.10 par value

AVD

New York Stock Exchange

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large Accelerated Filer

☐

Accelerated Filer

☒

Non-Accelerated Filer

☐

Smaller reporting company

☐

Emerging growth company

☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date. Common Stock, $0.10 Par Value—29,553,079 shares as of November 4, 2026.


AMERICAN VANGUARD CORPORATION

INDEX

Page Number

Part I. Financial Information

Item 1.

Financial Statements (unaudited)

Condensed Consolidated Statements of Operations

3

Condensed Consolidated Statements of Comprehensive Loss

4

Condensed Consolidated Balance Sheets

5

Condensed Consolidated Statements of Stockholders’ Equity

6

Condensed Consolidated Statements of Cash Flows

8

Notes to Condensed Consolidated Financial Statements

9

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

19

Item 3.

Quantitative and Qualitative Disclosures About Market Risk

27

Item 4.

Controls and Procedures

27

Part II. Other Information

Item 1.

Legal Proceedings

28

Item 1A.

Risk Factors

28

Item 2.

Purchases of Equity Securities by the Issuer

28

Item 6.

Exhibits

29

Signatures

30

2


Part I. Financial Information

Item 1. Financial Statements

AMERICAN VANGUARD CORPORATION AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(In thousands, except per share data)

(Unaudited)

For the Three Months Ended September 30,

For the Nine Months Ended September 30,

2026

2025

2026

2025

Net sales

$

108,376

$

119,313

$

348,698

$

364,426

Cost of sales

(82,124

)

(85,099

)

(249,316

)

(259,474

)

Gross profit

26,252

34,214

99,382

104,952

Operating expenses

Selling, general and administrative

(25,797

)

(26,747

)

(80,133

)

(81,998

)

Research, product development and regulatory

(5,342

)

(5,654

)

(17,097

)

(17,139

)

Product liability claims

(22

)

(7,029

)

(223

)

(7,029

)

CFO transition costs

(1,316

)

—

(1,316

)

—

Transformation

(1,665

)

(1,442

)

(5,975

)

(5,254

)

Asset impairments

—

(93

)

(943

)

(227

)

(Loss) gain from sale of assets

(75

)

246

(75

)

246

Operating loss

(7,965

)

(6,505

)

(6,380

)

(6,449

)

Change in fair value of an equity investment

(21

)

(511

)

(193

)

(511

)

Interest expense, net

(9,146

)

(4,920

)

(24,066

)

(13,135

)

Loss before provision for income taxes

(17,132

)

(11,936

)

(30,639

)

(20,095

)

Income tax expense

(536

)

(422

)

(1,043

)

(1,574

)

Net loss

$

(17,668

)

$

(12,358

)

$

(31,682

)

$

(21,669

)

Net loss per common share—basic

$

(0.61

)

$

(0.43

)

$

(1.10

)

$

(0.76

)

Net loss per common share—assuming dilution

$

(0.61

)

$

(0.43

)

$

(1.10

)

$

(0.76

)

Weighted average shares outstanding—basic

28,775

28,511

28,691

28,377

Weighted average shares outstanding—assuming dilution

28,775

28,511

28,691

28,377

See accompanying notes to the condensed consolidated financial statements.

3


AMERICAN VANGUARD CORPORATION AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS

(In thousands)

(Unaudited)

For the Three Months Ended September 30,

For the Nine Months Ended September 30,

2026

2025

2026

2025

Net loss

$

(17,668

)

$

(12,358

)

$

(31,682

)

$

(21,669

)

Other comprehensive (loss) income:

Foreign currency translation adjustment, net of tax effects

(1,130

)

1,473

1,131

7,323

Comprehensive loss

$

(18,798

)

$

(10,885

)

$

(30,551

)

$

(14,346

)

See accompanying notes to the condensed consolidated financial statements.

4


AMERICAN VANGUARD CORPORATION AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands, except share data)

(Unaudited)

ASSETS

September 30, 2026

December 31, 2025

Current assets:

Cash

$

83,909

$

12,425

Receivables:

Trade, net of allowance for credit losses of $14,336 and $11,733, respectively

142,677

160,511

Other

7,522

7,278

Total receivables, net

150,199

167,789

Inventories

194,079

176,034

Prepaid expenses

8,464

9,668

Income taxes receivable

1,750

4,606

Total current assets

438,401

370,522

Property, plant and equipment, net

51,956

53,036

Operating lease right-of-use assets, net

16,407

16,793

Intangible assets, net

139,809

138,746

Deferred income tax assets

2,963

2,637

Other assets

13,874

14,803

Total assets

$

663,410

$

596,537

Liabilities and Stockholders’ Equity

Current liabilities:

Accounts payable

$

86,325

$

87,505

Customer prepayments

44,621

33,094

Accrued program costs

46,825

52,227

Accrued expenses and other payables

26,704

28,261

Current portion of long-term debt

3,750

—

Operating lease liabilities, current

5,637

5,765

Income taxes payable

3,370

2,594

Total current liabilities

217,232

209,446

Long-term debt, net of current portion

263,937

174,000

Operating lease liabilities, long-term

11,243

11,621

Deferred income tax liabilities

7,115

8,150

Other liabilities

760

923

Total liabilities

500,287

404,140

Commitments and contingent liabilities (Note 12)

Stockholders’ equity:

Preferred stock, $0.10 par value per share; authorized 400,000 shares; none issued

—

—

Common stock, $0.10 par value per share; authorized 40,000,000 shares; issued 34,957,296 shares at September 30, 2026 and 34,923,562 shares at December 31, 2025

3,496

3,492

Additional paid-in capital

118,378

117,106

Accumulated other comprehensive loss

(10,869

)

(12,000

)

Retained earnings

123,319

155,000

234,324

263,598

Less treasury stock at cost, 5,915,182 shares at September 30, 2026 and December 31, 2025

(71,201

)

(71,201

)

Total stockholders’ equity

163,123

192,397

Total liabilities and stockholders’ equity

$

663,410

$

596,537

See accompanying notes to the condensed consolidated financial statements.

5


AMERICAN VANGUARD CORPORATION AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

For the Three and Nine Months Ended September 30, 2026

(In thousands, except share data)

(Unaudited)

Common Stock

Additional

Accumulated Other

Treasury Stock

Shares

Amount

Paid-in
  Capital

Comprehensive
Loss

Retained
Earnings

Shares

Amount

Total

Balance, January 1, 2026

34,923,562

$

3,492

$

117,106

$

(12,000

)

$

155,000

5,915,182

$

(71,201

)

$

192,397

Stocks issued under ESPP

68,714

7

256

—

—

—

—

263

Foreign currency translation adjustment, net

—

—

—

938

—

—

—

938

Stock-based compensation

—

—

186

—

—

—

—

186

Stock options exercised; grants,
   termination and vesting of
   restricted stock units
   (net of shares in lieu of taxes)

(12,501

)

(1

)

(18

)

—

—

—

—

(19

)

Net loss

—

—

—

—

(4,145

)

—

—

(4,145

)

Balance, March 31, 2026

34,979,775

$

3,498

$

117,530

$

(11,062

)

$

150,855

5,915,182

$

(71,201

)

$

189,620

Foreign currency translation adjustment, net

—

—

—

1,323

—

—

—

1,323

Stock-based compensation

—

—

388

—

—

—

—

388

Stock options exercised; grants,
   termination and vesting of
   restricted stock units
   (net of shares in lieu of taxes)

(128,836

)

(13

)

(63

)

—

—

—

—

(76

)

Net loss

—

—

—

—

(9,868

)

—

—

(9,868

)

Balance, June 30, 2026

34,850,939

$

3,485

$

117,855

$

(9,739

)

$

140,987

5,915,182

$

(71,201

)

$

181,387

Foreign currency translation adjustment, net

—

—

—

(1,130

)

—

—

—

(1,130

)

Stocks issued under ESPP

75,713

8

203

—

—

—

—

211

Stock-based compensation

—

—

327

—

—

—

—

327

Stock options exercised; grants,
   termination and vesting of
   restricted stock units
   (net of shares in lieu of taxes)

30,644

3

(7

)

—

—

—

—

(4

)

Net loss

—

—

—

—

(17,668

)

—

—

(17,668

)

Balance, September 30, 2026

34,957,296

$

3,496

$

118,378

$

(10,869

)

$

123,319

5,915,182

$

(71,201

)

$

163,123

See accompanying notes to the condensed consolidated financial statements.

6


AMERICAN VANGUARD CORPORATION AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

For the Three and Nine Months Ended September 30, 2025

(In thousands, except share data)

(Unaudited)

Common Stock

Additional

Accumulated Other

Treasury Stock

Shares

Amount

Paid-in
  Capital

Comprehensive
Loss

Retained
Earnings

Shares

Amount

Total

Balance, January 1, 2025

34,794,548

$

3,479

$

114,679

$

(18,729

)

$

204,882

5,915,182

$

(71,201

)

$

233,110

Stocks issued under ESPP

72,267

7

326

—

—

—

—

333

Foreign currency translation adjustment, net

—

—

—

1,825

—

—

—

1,825

Stock-based compensation

—

—

559

—

—

—

—

559

Stock options exercised; grants,
   termination and vesting of
   restricted stock units
   (net of shares in lieu of taxes)

(16,785

)

(1

)

(10

)

—

—

—

—

(11

)

Net loss

—

—

—

—

(8,462

)

—

—

(8,462

)

Balance, March 31, 2025

34,850,030

$

3,485

$

115,554

$

(16,904

)

$

196,420

5,915,182

$

(71,201

)

$

227,354

Foreign currency translation adjustment, net

—

—

—

4,025

—

—

—

4,025

Stock-based compensation

—

—

422

—

—

—

—

422

Stock options exercised; grants,
   termination and vesting of
   restricted stock units
   (net of shares in lieu of taxes)

(71,607

)

(7

)

(123

)

—

—

—

—

(130

)

Net loss

—

—

—

—

(849

)

—

—

(849

)

Balance, June 30, 2025

34,778,423

$

3,478

$

115,853

$

(12,879

)

$

195,571

5,915,182

$

(71,201

)

$

230,822

Stocks issued under ESPP

75,930

8

288

—

—

—

—

296

Foreign currency translation adjustment, net

—

—

—

1,473

—

—

—

1,473

Stock-based compensation

—

—

760

—

—

—

—

760

Stock options exercised; grants, termination
   and vesting of restricted stock units
   (net of shares in lieu of taxes)

116,334

11

(16

)

—

—

—

—

(5

)

Net loss

—

—

—

—

(12,358

)

—

—

(12,358

)

Balance, September 30, 2025

34,970,687

$

3,497

$

116,885

$

(11,406

)

$

183,213

5,915,182

$

(71,201

)

$

220,988

See accompanying notes to the condensed consolidated financial statements.

7


AMERICAN VANGUARD CORPORATION AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands)

(Unaudited)

For the Nine Months Ended September 30,

2026

2025

Cash flows from operating activities:

Net loss

$

(31,682

)

$

(21,669

)

Adjustments to reconcile net loss to net cash used in operating activities:

Depreciation and amortization of property, plant and equipment and intangible assets

13,442

14,007

Amortization of other long-term assets

5

16

Loss (gain) on disposal of property, plant and equipment

75

(246

)

Provision for estimated credit losses

2,469

1,944

Stock-based compensation

901

1,741

Deferred income taxes

(1,073

)

(353

)

Change in liabilities for uncertain tax positions or unrecognized tax benefits

(127

)

(522

)

Change in equity investment fair value

193

511

Impairment of assets

943

227

Payment-in-kind debt leverage fee

1,261

—

Amortization of deferred loan fees

2,899

1,167

Lease obligations and non-cash lease expense, net

(120

)

(150

)

Unrealized foreign currency transaction losses (gains)

243

(704

)

Changes in assets and liabilities associated with operations:

Decrease in net receivables

14,812

935

Increase in inventories

(16,007

)

(16,513

)

Increase in prepaid expenses and other assets

(1,039

)

(965

)

Change in income tax receivable and payable, net

3,526

(1,083

)

(Decrease) increase in accounts payable

(960

)

11,859

Increase (decrease) in customer prepayments

11,527

(21,453

)

(Decrease) increase in accrued program costs

(5,454

)

12,285

Decrease in other payables and accrued expenses

(8,180

)

(8,178

)

Net cash used in operating activities

(12,346

)

(27,144

)

Cash flows from investing activities:

Capital expenditures

(4,676

)

(2,398

)

Proceeds from disposal of property, plant and equipment

10

492

Intangible assets

(5,149

)

(136

)

Net cash used in investing activities

(9,815

)

(2,042

)

Cash flows from financing activities:

Payments under line of credit agreement

(140,000

)

(179,415

)

Borrowings under line of credit agreement

26,000

214,334

Borrowings under term loans

225,000

—

Repayments of term loans

(1,125

)

—

Payment of deferred loan fees

(16,581

)

(3,339

)

Net receipt from the issuance of common stock under ESPP

474

629

Net payment from common stock purchased for tax withholding

(99

)

(147

)

Net cash provided by financing activities

93,669

32,062

Net increase in cash

71,508

2,876

Effect of exchange rate changes on cash and cash equivalents

(24

)

1,405

Cash at beginning of period

12,425

12,514

Cash at end of period

$

83,909

$

16,795

See accompanying notes to the condensed consolidated financial statements.

8


AMERICAN VANGUARD CORPORATION AND SUBSIDIARIES

Notes to the Condensed Consolidated Financial Statements

(In thousands, except share data)

(Unaudited)

1. Summary of Significant Accounting Policies

The accompanying unaudited condensed consolidated financial statements of American Vanguard Corporation and its subsidiaries (“AVD” or “the Company”) have been prepared in accordance with generally accepted accounting principles in the United States of America (“US GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. In the opinion of management, all adjustments (consisting of consolidating adjustments, eliminations, and normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the three and nine months ended September 30, 2026, are not necessarily indicative of the results that may be expected for the year ending December 31, 2026. The condensed consolidated financial statements and related notes do not include all information and footnotes required by US GAAP for annual reports. This quarterly report should be read in conjunction with the consolidated financial statements included in the Company’s annual report on Form 10-K for the year ended December 31, 2025.

CFO Transition Costs — The Chief Financial Officer (“CFO”) transition costs include severance costs payable to the outgoing CFO and executive search costs for the new CFO.

Transformation — Transformation expenses on the condensed consolidated statements of operations relate to three initiatives: digital transformation, structural transformation and manufacturing optimization. The digital transformation is intended to give business process owners access to current and complete data generated through standardized systems and processes. The structural transformation is intended to improve operating leverage by applying business analytics to the Company’s operations, structures, products and services to identify process and structural improvements, as well as pricing and go-to-market strategies. The manufacturing optimization is focused on the Company’s U.S. manufacturing footprint. It reduces activities at the Los Angeles facility, including discontinuing synthesis processes at that site, and builds upon the capabilities of the Axis manufacturing site. Transformation expenses consist primarily of consulting fees, costs of staffing and executing the transformation initiatives, and costs of the Los Angeles plant reorganization. Transformation expenses were $1,665 and $5,975 for the three and nine months ended September 30, 2026, respectively, and $1,442 and $5,254 for the three and nine months ended September 30, 2025, respectively.

The Los Angeles plant reorganization is expected to be completed by December 31, 2026. Reorganization costs, which are included in transformation expenses, were $226 and $3,341 for the three and nine months ended September 30, 2026, respectively. For the three months ended September 30, 2026, all of these costs were personnel costs for cleaning up the plant and transferring production. For the nine months ended September 30, 2026, they consisted of severance of $932, personnel costs for plant clean-up and production transfer of $908, waste disposal of $390, and other costs of $1,111. The Company also recorded impairment charges of $943 for the nine months ended September 30, 2026 on Los Angeles plant assets that became idle because of the reorganization. There were no such charges for the three months ended September 30, 2026. These charges are included in asset impairments, not in transformation expenses. No reorganization costs or related impairment charges were incurred in the three or nine months ended September 30, 2025.

Recently Adopted Accounting Guidance — In July 2025, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2025-05, “Financial Instruments - Credit Losses,” which simplifies the application of the current expected credit loss model by providing a practical expedient and accounting policy election permitting entities to assume that conditions as of the balance sheet date remain unchanged over the life of the asset when measuring credit losses on current accounts receivable and current contract assets. The Company's adoption of this standard on January 1, 2026, had no impact on its disclosures and no material impact on its results of operations, cash flows or financial condition.

Recently Issued Accounting Guidance — In November 2024, the FASB issued ASU No. 2024-03, "Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses", and in January 2025, the FASB issued ASU No. 2025-01, "Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Clarifying the Effective Date". ASU 2024-03 requires public companies to disclose, in interim and reporting periods, additional information about certain expenses in the financial statements. For public business entities, ASU 2024-03, as clarified by ASU 2025-01, is effective for the first annual reporting period beginning after December 15, 2026, and interim reporting periods within annual reporting periods beginning after December 15, 2027. Early adoption of ASU 2024-03 is permitted. The Company is currently evaluating the impact of adopting this ASU on its consolidated financial statements.

The Company reviewed all other recently issued accounting pronouncements and concluded that they were either not applicable to, or not expected to have a significant impact upon, its condensed consolidated financial statements.

9


AMERICAN VANGUARD CORPORATION AND SUBSIDIARIES

Notes to the Condensed Consolidated Financial Statements – (Continued)

(In thousands, except share data)

(Unaudited)

Reclassification — Certain amounts in the accompanying condensed consolidated statements of operations and cash flows have been reclassified to conform to the current period financial statements. These reclassifications have not changed the results of operations or cash flows of the prior period.

2. Revenue Recognition

The Company recognizes revenue from the sale of its products, which include Crop and Specialty products. The Company sells its products to customers, which include distributors, retailers, and growers. Substantially all revenue is recognized at a point in time. The Company has one reportable segment. Selective enterprise information of sales disaggregated by category and geographic region is as follows:

Three Months Ended September 30,

Nine Months Ended September 30,

2026

2025

2026

2025

Net sales:

U.S. Crop

$

42,316

$

43,310

$

157,510

$

153,511

U.S. Specialty

18,872

19,233

57,045

54,067

Total U.S.

61,188

62,543

214,555

207,578

International

47,188

56,770

134,143

156,848

Total net sales:

$

108,376

$

119,313

$

348,698

$

364,426

Net sales are reported within the country of the selling entity. As of October 1, 2025, the Company implemented a new organizational structure, as part of its business transformation actions, and now sells and recognizes direct business-to-business sales to certain foreign customers in its U.S. Crop business. The associated sales are reported as U.S. Crop net sales for the three and nine months ended September 30, 2026. For the three and nine months ended September 30, 2025, these sales were included in International net sales and amounted to $5,170 and $15,863, respectively. These prior period amounts have not been restated and are provided for comparability purposes only.

The Company sometimes receives payments from its customers in advance of goods and services being provided in return for early cash incentive programs. These payments are included in customer prepayments on the condensed consolidated balance sheets. Revenue recognized for the three and nine months ended September 30, 2026, that was included in customer prepayments at the beginning of 2026, was $654 and $33,007, respectively.

The Company has contract assets that relate to royalties earned on certain functional licenses granted for the use of the Company’s intellectual property. At September 30, 2026 and December 31, 2025, the contract assets amounted to $8,250 and are included in other assets on the condensed consolidated balance sheets.

3. Accrued Program Costs

The Company offers various discounts to customers based on the volume purchased within a defined period, other pricing adjustments, some grower volume incentives or other key performance indicator driven payments made to distributors, retailers or growers, usually at the end of a growing season. The Company describes these payments as “Programs.” Programs are a critical part of doing business in both the U.S. Crop and Specialty chemicals marketplaces. These discount Programs represent variable consideration. Revenues from sales are recorded at the net sales price, which is the transaction price, less an estimate of variable consideration. Variable consideration includes amounts expected to be paid to its customers using the expected value method. Each quarter management compares individual sale transactions with Programs to determine what, if any, Program liabilities have been incurred. Once this initial calculation is made for the specific quarter, sales and marketing management, along with executive and financial management, review the accumulated Program balance and, for volume driven payments, make assessments of whether or not customers are tracking in a manner that indicates that they will meet the requirements set out in agreed upon terms and conditions attached to each Program. Following this assessment, management adjusts the accumulated accrual to properly reflect the liability at the balance sheet date. Programs are paid out predominantly on an annual basis, usually in the final quarter of the financial year or the first quarter of the following year.

10


AMERICAN VANGUARD CORPORATION AND SUBSIDIARIES

Notes to the Condensed Consolidated Financial Statements – (Continued)

(In thousands, except share data)

(Unaudited)

4. Income Taxes

Income tax expense was $536 for the three months ended September 30, 2026, as compared to $422 for the three months ended September 30, 2025. Income tax expense was $1,043 for the nine months ended September 30, 2026, as compared to $1,574 for the nine months ended September 30, 2025. The effective income tax rate for the three and nine months ended September 30, 2026, was computed based on the estimated effective tax rate for the full year. This calculation resulted in an effective tax rate of negative 3.13% for the three months ended September 30, 2026, as compared to negative 3.53% for the three months ended September 30, 2025. The effective income tax rate was negative 3.41% for the nine months ended September 30, 2026, as compared to negative 7.83% for the nine months ended September 30, 2025. The increase in the effective income tax rate for the three and nine months ended September 30, 2026, compared to the same period in the prior year is primarily attributed to a reduction in the estimated effective tax rate for the full year primarily for the profitable entities with no established valuation allowance. The Company continues to maintain valuation allowances established against the net deferred tax assets of the U.S. and certain international entities, primarily in Brazil, for the three and nine months ended September 30, 2026. During the three and nine months ended September 30, 2026, several of the Company’s international businesses outside of Brazil were profitable, resulting in an income tax expense.

5. Earnings Per Share

The components of basic and diluted earnings per share were as follows:

Three Months Ended September 30,

Nine Months Ended September 30,

2026

2025

2026

2025

Numerator:

Net loss

$

(17,668

)

$

(12,358

)

$

(31,682

)

$

(21,669

)

Denominator:

Weighted average shares outstanding-basic and diluted

28,775

28,511

28,691

28,377

Due to net losses for the three and nine months ended September 30, 2026 and 2025, stock options and other grants were excluded from the computation of diluted net loss per share, as they would be antidilutive.

6. Comprehensive Loss

Total comprehensive loss includes, in addition to net losses, changes in equity that are excluded from the condensed consolidated statements of operations and are recorded directly into a separate section of stockholders’ equity on the condensed consolidated balance sheets. For the three and nine months ended September 30, 2026 and 2025, total comprehensive loss consisted of net losses and foreign currency translation adjustments.

7. Inventories

Inventory is stated at the lower of cost or net realizable value. Cost is determined by the average cost method, and includes material, labor, factory overhead and subcontracting services.

September 30, 2026

December 31, 2025

Finished products

$

173,674

$

148,961

Raw materials

20,405

27,073

Inventories

$

194,079

$

176,034

Finished products consist of products that are sold to customers in their current form as well as intermediate products that require further formulation to be saleable to customers.

11


AMERICAN VANGUARD CORPORATION AND SUBSIDIARIES

Notes to the Condensed Consolidated Financial Statements – (Continued)

(In thousands, except share data)

(Unaudited)

8. Property, Plant and Equipment

Property, plant and equipment at September 30, 2026, and December 31, 2025, consist of the following:

September 30, 2026

December 31, 2025

Land

$

2,761

$

2,761

Buildings and improvements

20,700

20,494

Machinery and equipment

150,556

149,715

Office furniture, fixtures and equipment

6,033

5,799

Automotive equipment

1,017

910

Construction in progress

4,420

2,094

Total

185,487

181,773

Less accumulated depreciation

(133,531

)

(128,737

)

Property, plant and equipment, net

$

51,956

$

53,036

The Company recognized depreciation expenses related to property and equipment of $1,588 and $1,622 for the three months ended September 30, 2026 and 2025, respectively, and $4,767 and $4,960 for the nine months ended September 30, 2026 and 2025, respectively.

Substantially all of the Company’s assets are pledged as collateral with its lender banks.

9. Leases

The Company has operating leases for certain of its warehouses, manufacturing facilities, offices, cars, railcars and certain equipment. The lease term under such leases includes the non-cancellable period of the lease plus any additional periods covered by either an option to extend (or not terminate) that the Company is reasonably certain to exercise. The Company has leases with a lease term ranging from one year to approximately 20 years.

The operating lease expense for the three months ended September 30, 2026 and 2025 was $1,680 and $1,895, respectively, and $5,251 and $5,584 for the nine months ended September 30, 2026 and 2025, respectively. Lease expenses related to variable lease payments and short-term leases were immaterial.

Other information related to operating leases were as follows:

Three Months Ended September 30,

Nine Months Ended September 30,

2026

2025

2026

2025

Cash paid for amounts included in the measurement of lease liabilities

$

1,660

$

1,945

$

5,265

$

5,733

Right-of-use assets obtained in exchange for new liabilities

$

1,851

$

1,040

$

4,505

$

3,049

The weighted-average remaining lease term and discount rate related to the operating leases as of September 30, 2026 were as follows:

Weighted-average remaining lease term (in years)

3.65

Weighted-average discount rate

5.78

%

12


AMERICAN VANGUARD CORPORATION AND SUBSIDIARIES

Notes to the Condensed Consolidated Financial Statements – (Continued)

(In thousands, except share data)

(Unaudited)

Future minimum lease payments under non-cancellable operating leases as of September 30, 2026, were as follows:

2026

1,682

2027

5,909

2028

4,261

2029

3,193

2030

2,076

Thereafter

1,561

Total lease payments

$

18,682

Less: imputed interest

(1,802

)

Total

$

16,880

Amounts recognized in the condensed consolidated balance sheet:

Operating lease liabilities, current

$

5,637

Operating lease liabilities, long-term

$

11,243

10. Intangibles

The following schedule represents the gross carrying amount and accumulated amortization of intangible assets as of September 30, 2026, and December 31, 2025. Product rights and trademarks are amortized over the lesser of the useful life ranging from 10 to 25 years, or the patent life. Customer lists are amortized over their expected useful lives of nine to ten years. The amortization expense is included in operating expenses on the condensed consolidated statements of operations.

September 30, 2026

December 31, 2025

Gross

Accumulated
Amortization

Net Book
Value

Gross

Accumulated
Amortization

Net Book
Value

Product rights, trademarks and patents

$

311,678

$

173,890

$

137,788

$

301,457

$

165,418

$

136,039

Customer lists

12,581

10,560

2,021

12,328

9,621

2,707

Total intangibles assets

$

324,259

$

184,450

$

139,809

$

313,785

$

175,039

$

138,746

Domestic intangible assets

183,706

116,027

67,679

173,898

109,885

64,013

International intangible assets

140,553

68,423

72,130

139,887

65,154

74,733

Total intangibles assets - domestic and international

$

324,259

$

184,450

$

139,809

$

313,785

$

175,039

$

138,746

The following schedule represents intangible assets activity for the nine months ended September 30, 2026:

Amount

Intangible assets at January 1, 2026

$

138,746

Additions during Q1 2026

9

Impact of movement in exchange rates

345

Amortization expense

(3,029

)

Intangible assets at March 31, 2026

$

136,071

Additions during Q2 2026

98

Impact of movement in exchange rates

46

Amortization expense

(3,030

)

Intangible assets at June 30, 2026

$

133,185

Additions during Q3 2026

9,560

Impact of movement in exchange rates

94

Amortization expense

(3,030

)

Intangible assets at September 30, 2026

$

139,809

13


AMERICAN VANGUARD CORPORATION AND SUBSIDIARIES

Notes to the Condensed Consolidated Financial Statements – (Continued)

(In thousands, except share data)

(Unaudited)

The following schedule represents future amortization charges related to intangible assets:

Year ending December 31,

Amount

2026

$

3,125

2027

12,420

2028

11,380

2029

11,081

2030

10,928

Thereafter

90,875

$

139,809

During the three months ended September 30, 2026 and 2025, amortization expense was $3,030 and $2,932, respectively, and $9,089 and $9,047 during the nine months ended September 30, 2026 and 2025, respectively.

On September 30, 2026, the Company acquired assets relating to four product lines within the U.S. market and paid $5,000 in cash to the seller. In addition, the Company has an obligation to pay $4,500 on the one-year anniversary of the acquisition. The Company also acquired inventory in the amount of $1,312 from the seller and will also acquire the seller’s planned 2026 inventory production, which is expected to be approximately $800. The acquisition was accounted for as an asset acquisition. The acquired assets included product and active ingredient registrations, trademarks, and inventory and were included in the Company’s condensed consolidated financial statements as of the date of the acquisition.

11. Debt

The Company had two term loans outstanding at September 30, 2026. At December 31, 2025, the Company had a revolving line of credit. The following summarizes the Company’s outstanding debt.

Long-term indebtedness ($000's)

September 30, 2026

December 31, 2025

Current portion of long-term debt

$

3,750

$

—

Long-term debt, net of current portion

281,288

174,000

Unamortized debt discount and debt issuance costs

(17,351

)

(3,015

)

Total indebtedness, net of unamortized debt discount and debt issuance costs

$

267,687

$

170,985

At September 30, 2026, long-term debt is related to two term loans that were put in place on March 13, 2026, and the balance is presented net of unamortized debt discount and debt issuance costs on the condensed consolidated balance sheets. At December 31, 2025, the Company had a revolving line of credit and the related unamortized debt issuance costs are included in prepaid expenses on the condensed consolidated balance sheets.

On March 13, 2026, AMVAC Chemical Corporation (“AMVAC”), a subsidiary of the Company, as borrower, and certain affiliates of the Company (including the Company), as guarantors, entered into (i) a Credit and Guaranty Agreement (the “First Lien Term Loan”) with a group of commercial lenders led by Centerbridge Partners, L.P., and Wilmington Trust, National Association as administrative agent; (ii) a Credit and Guaranty Agreement (the “Second Lien Term Loan” and, together with the First Lien Term Loan, the “Term Loans”) with a group of commercial lenders led by BMO Bank N.A., as sole lead arranger and book runner, and BMO Bank N.A. as administrative agent; and (iii) an Intercreditor Agreement by and among Wilmington Trust, National Association, as first lien agent, BMO Bank N.A., as second lien agent, and the secured creditors from time to time party thereto. The proceeds of the Term Loans, were used, among other things, to refinance in full and retire existing indebtedness under the Third Amended and Restated Credit Agreement, dated as of August 5, 2021, to pay related fees and expenses, and will also be used for other general corporate and working capital purposes permitted under the Term Loans.

First Lien Term Loan

The First Lien Term Loan is a senior secured term loan facility with a five year term for an aggregate principal amount of $225,000 that matures on March 13, 2031. The First Lien Term Loan contains customary representations and warranties, affirmative and negative covenants and events of default for financings of this type. AMVAC is obligated to pay the principal amount in consecutive quarterly installments commencing as of June 30, 2026, in an amount for each such fiscal quarter equal to 0.25% of the

14


AMERICAN VANGUARD CORPORATION AND SUBSIDIARIES

Notes to the Condensed Consolidated Financial Statements – (Continued)

(In thousands, except share data)

(Unaudited)

original principal amount. The unpaid principal amount shall be due and payable in full on the maturity date. AMVAC is required to make mandatory prepayments of the First Lien Term Loan in certain circumstances (e.g. the disposition of certain collateralized assets) and is permitted to make voluntary prepayments subject to payment of an applicable prepayment premium during the first 48 months following closing, in each case, in accordance with the terms of the First Lien Term Loan. Interest is based on a specified benchmark rate (including, as applicable, a Secured Overnight Financing Rate (“SOFR”)-based rate) plus an applicable margin initially equal to 8.25% per annum for SOFR loans (or 7.25% per annum for base rate loans), subject to step-downs based on the Company’s consolidated total leverage ratio, or an alternate base rate, as described in the First Lien Term Loan. In addition, a leverage fee of 1.00% per annum, payable in kind, is payable on the outstanding term loans for so long as the Company’s consolidated total leverage ratio exceeds 5.00:1.00.

The Company is also subject to a consolidated total leverage ratio at the end of each quarterly period, with calculation terms defined under the First Lien Term Loan, of the funded indebtedness of the consolidated group to consolidated EBITDA for the trailing twelve months that shall not be greater than 6.70 to 1.00 for the quarters ending March 31, 2026 to December 31, 2026, 6.13 to 1.00 for the quarter ending March 31, 2027, 5.68 to 1.00 for the quarter ending June 30, 2027, 5.23 to 1.00 for the quarter ending September 30, 2027, 4.78 to 1.00 for the quarter ending December 31, 2027, 4.44 to 1.00 for the quarter ending March 31, 2028, 4.19 to 1.00 for the quarter ending June 30, 2028, 4.02 to 1.00 for the quarter ending September 30, 2028, and 4.00 to 1.00 for the quarters ending December 31, 2028 and thereafter. AMVAC and the guarantors are also required to maintain minimum unrestricted cash and cash equivalents of $30,000 for the month ending September 30, 2026, $35,000 for the months ending October 31, 2026 to November 30, 2026, $40,000 for the months ending December 31, 2026 to September 30, 2027, $45,000 for the months ending October 31, 2027 to December 31, 2027, and $50,000 for the months ending January 31, 2028 and thereafter. The Company’s ability to remain in compliance with the leverage covenant under its First Lien Term Loan depends on generating significant adjusted EBITDA during the fourth quarter of 2026.

Second Lien Term Loan

The Second Lien Term Loan is a secured term loan facility with a five-year term for an aggregate principal amount of $60,000 that matures on March 13, 2031. The Second Lien Term Loan contains customary representations and warranties, affirmative and negative covenants and events of default for financings of this type. AMVAC is required to make mandatory prepayments of the Second Lien Term Loan in certain circumstances and is permitted to make voluntary prepayments without premium or penalty, in each case, in accordance with the terms of the Second Lien Term Loan. Interest is based on a specified benchmark rate (including, as applicable, a SOFR-based rate) plus an applicable margin of 2.00% per annum, subject to a SOFR floor of 3.00%, or an alternate base rate, as described in the Second Lien Term Loan.

Pursuant to the terms of the First Lien Term Loan and Second Lien Term Loan, the Company is prevented from paying cash dividends to shareholders.

The weighted average interest rate for the three and nine months ended September 30, 2026 was 12.9% and 12.4%, respectively. Total interest expense (including leverage fees and amortization of deferred loan fees) was $9,474 and $4,912 for the three months ended September 30, 2026 and 2025, respectively, and $24,636 and $13,141 for the nine months ended September 30, 2026 and 2025, respectively.

As of September 30, 2026, the Company is in compliance with its financial covenants.

15


AMERICAN VANGUARD CORPORATION AND SUBSIDIARIES

Notes to the Condensed Consolidated Financial Statements

(In thousands, except share data)

(Unaudited)

12. Commitments and Contingencies

The Company records a liability on its condensed consolidated financial statements for loss contingencies when a loss is known or considered probable, and the amount can be reasonably estimated. When determining the estimated loss or range of loss, significant judgment is required to estimate the amount and timing of a loss to be recorded. The Company recognizes legal expenses in connection with loss contingencies as incurred. Except as otherwise described below, there have been no material changes in previously reported litigation matters since the filing of the Company's Form 10-K for the period ended December 31, 2025, or the filings of the Company’s Form 10-Q for the periods ended March 31, 2026 and June 30, 2026:

Chavez & Marquinez. Two cases were filed independently in 2012 in Louisiana and Delaware involving claims on behalf of banana workers for personal injury allegedly arising from exposure to DBCP in the late 1970’s. Through several years of law and motion practice, the number of plaintiffs in the actions has been reduced from about 2,750 to 290, all of whom are banana workers from Costa Rica, Ecuador, Guatemala and Panama, and both cases have been consolidated before the United States District Court for the District of Delaware (USDC DE No. 1:12-CV-00695 & 00697). Discovery commenced in 2018 and has largely concluded. Further, the court has segregated plaintiffs into several small groups (including eight trials groups of ~20 Ecuadoreans in total) for trial. The first group of Ecuadorean plaintiffs was to go to trial in Q4, 2026; however, in June 2026, the court granted AMVAC’s motion for summary judgment on the ground that “there is no evidence that any of the plaintiffs say that they had exposure to AMVAC’s product.” To the Company’s knowledge, none of the plaintiffs has produced any evidence to the contrary. Further, during the third quarter of 2026, in response to defendants’ filed motions for summary judgment and under Daubert (challenging the admissibility of plaintiffs’ expert testimony), the court took the trial schedule off calendar. The Company does not believe that a loss is probable or reasonably estimable and has not recorded a loss contingency for these matters.

13. Accumulated Other Comprehensive Loss

The following table lists the beginning balance, activity and ending balance of foreign currency translation adjustment included as a component of accumulated other comprehensive loss:

Total

Balance, January 1, 2026

$

(12,000

)

Foreign currency translation adjustment, net of tax effects of ($0)

938

Balance, March 31, 2026

$

(11,062

)

Foreign currency translation adjustment, net of tax effects of ($15)

1,323

Balance, June 30, 2026

$

(9,739

)

Foreign currency translation adjustment, net of tax effects of ($3)

(1,130

)

Balance, September 30, 2026

$

(10,869

)

Balance, January 1, 2025

$

(18,729

)

Foreign currency translation adjustment, net of tax effects of ($4)

1,825

Balance, March 31, 2025

$

(16,904

)

Foreign currency translation adjustment, net of tax effects of ($30)

4,025

Balance, June 30, 2025

$

(12,879

)

Foreign currency translation adjustment, net of tax effects of ($13)

1,473

Balance, September 30, 2025

$

(11,406

)

16


AMERICAN VANGUARD CORPORATION AND SUBSIDIARIES

Notes to the Condensed Consolidated Financial Statements

(In thousands, except share data)

(Unaudited)

14. Fair Value of Financial Instruments

The accounting standard for fair value measurements provides a framework for measuring fair value and requires expanded disclosures regarding fair value measurements. Fair value is defined as the price that would be received for an asset or the exit price that would be paid to transfer a liability in the principal or most advantageous market in an orderly transaction between market participants on the measurement date. This accounting standard establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs, where available. The following summarizes the three levels of inputs required:

•

Level 1 – Quoted prices in active markets for identical assets or liabilities.

•

Level 2 – Observable inputs other than quoted prices in active markets for identical assets and liabilities, quoted prices for identical or similar assets or liabilities in inactive markets, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

•

Level 3 – Inputs that are generally unobservable and typically reflect management’s estimate of assumptions that market participants would use in pricing the asset or liability.

The carrying amount of the Company’s financial instruments, which primarily include cash and cash equivalents, accounts receivable, accounts payable and accrued expenses, approximates fair value because of the relatively short maturity of such instruments. The carrying amount of the Company’s borrowings, which are considered Level 2 liabilities, approximates fair value as they bear interest at a variable rate at current market rates.

15. Supplemental Cash Flow Information

For the Nine Months Ended September 30,

Cash paid during the period:

2026

2025

Interest

$

19,252

$

12,023

Income taxes, net of refunds

$

(1,215

)

$

3,164

Non-cash transactions:

Debt refinancing

$

60,000

$

—

Acquisition of product lines and inventory

$

5,812

$

—

Additions to debt issuance costs

$

713

$

—

As of September 30,

Reconciliation of unrestricted cash and restricted cash reported in the condensed consolidated balance sheets

2026

2025

Unrestricted cash

$

83,342

$

16,795

Restricted cash

567

—

Total cash

$

83,909

$

16,795

The Company maintains cash balances that exceed federally insured limits with a number of financial institutions. Cash includes legally restricted deposits held as compensating balances against the credit limit of one of the Company’s credit cards.

17


AMERICAN VANGUARD CORPORATION AND SUBSIDIARIES

Notes to the Condensed Consolidated Financial Statements

(In thousands, except share data)

(Unaudited)

16. Segment Reporting

The Company operates as a single operating segment, which is the business of developing, manufacturing and distributing chemical, biological and biorational products for agricultural, commercial and consumer uses. The Company synthesizes and formulates chemicals and ferments and extracts microbial products for crops, turf, ornamental plants, and human and animal health protection.

The Company’s Chief Operating Decision Maker (“CODM”) is the Chief Executive Officer, who manages the Company’s operations based on consolidated financial information for purposes of evaluating financial performance and allocating resources. The financial information reviewed by the CODM includes revenue by product line and region, and key expense categories that are regularly provided for the consolidated company. The accounting policies of the Company’s single operating segment are the same as those described in the summary of significant accounting policies. Although there are other measures of operating performance used by the CODM, the Company concluded that consolidated operating (loss) income is the measure required to be disclosed as the segment measure of profit or loss. Operating (loss) income is utilized to evaluate to monitor budget versus actual results in order to gain more depth and understanding of the factors driving the business. When evaluating the Company’s financial performance, the following table sets forth significant expense categories regularly provided to the CODM:

For the Three Months Ended September 30,

For the Nine Months Ended September 30,

2026

2025

2026

2025

Net sales

$

108,376

$

119,313

$

348,698

$

364,426

Cost of sales

Material and other costs

(69,655

)

(74,069

)

(215,937

)

(229,335

)

Warehousing, handling, and outbound freight

(12,469

)

(11,030

)

(33,379

)

(30,139

)

Total cost of sales

(82,124

)

(85,099

)

(249,316

)

(259,474

)

Gross profit

26,252

34,214

99,382

104,952

Operating expenses

Selling, general and administrative

(25,797

)

(26,747

)

(80,133

)

(81,998

)

Research, product development and regulatory

(5,342

)

(5,654

)

(17,097

)

(17,139

)

Product liability claims

(22

)

(7,029

)

(223

)

(7,029

)

CFO transition costs

(1,316

)

—

(1,316

)

—

Transformation

(1,665

)

(1,442

)

(5,975

)

(5,254

)

Asset impairments

—

(93

)

(943

)

(227

)

(Loss) gain from sale of assets

(75

)

246

(75

)

246

Operating loss

(7,965

)

(6,505

)

(6,380

)

(6,449

)

Change in fair value of an equity investment

(21

)

(511

)

(193

)

(511

)

Interest expense, net

(9,146

)

(4,920

)

(24,066

)

(13,135

)

Loss before provision for income taxes

(17,132

)

(11,936

)

(30,639

)

(20,095

)

Income tax expense

(536

)

(422

)

(1,043

)

(1,574

)

Net loss

$

(17,668

)

$

(12,358

)

$

(31,682

)

$

(21,669

)

Asset categories provided to the CODM are consistent with those reported on the condensed consolidated balance sheets.

18


Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations (Numbers in thousands)

Forward-Looking Statements/Risk Factors:

The Company, from time-to-time, may discuss forward-looking statements including assumptions concerning the Company’s operations, future results and prospects. Generally, “may,” “could,” “will,” “would,” “expect,” “believe,” “estimate,” “anticipate,” “intend,” “continue” and similar words identify forward-looking statements. Forward-looking statements appearing in this report are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on our current expectations and are subject to risks and uncertainties that can cause actual results and events to differ materially from those set forth in or implied by the forward-looking statements and related assumptions contained in the entire report. Such factors include, but are not limited to: product demand and market acceptance risks; the effect of economic conditions; weather conditions; military activity and other geopolitical activity; fuel and freight cost increases arising from geopolitical turmoil; the imposition and removal of tariffs; changes in regulatory policy; the impact of competitive products and pricing; changes in foreign exchange rates; product development and commercialization difficulties; capacity and supply constraints or difficulties; availability of capital resources given that interest rate and inflation affect the debt market; and general business regulations, including taxes and other risks as detailed from time-to-time in the Company’s reports and filings filed with the U.S. Securities and Exchange Commission (“SEC”). It is not possible to foresee or identify all such factors. We urge you to consider these factors carefully in evaluating the forward-looking statements contained in this report. You should evaluate all forward-looking statements made in this Form 10-Q in the context of the risks and uncertainties disclosed in Part II, Item 1A of this Form 10-Q under the heading "Risk Factors," in Part I, Item 2 "Management's Discussion and Analysis of Financial Condition and Results of Operations," and in Item 3 "Quantitative and Qualitative Disclosures About Market Risk."

The forward-looking statements included in this Form 10-Q are made only as of the date hereof. We undertake no obligation to publicly update or revise any forward-looking statement as a result of new information, future events or otherwise, except as otherwise required by law. If we do update one or more forward-looking statements, no inference should be made that we will make additional updates with respect to those or other forward-looking statements.

Three Months Ended September 30, 2026 and 2025:

Overview of the Company’s Performance

Even with modest increases in row crop commodity prices, farm income was down due to significant increases in diesel fuel and fertilizer expenses. Further, U.S. government payments to growers as a percentage of income rose from about 25% to over 40%. With increasing cost of capital and uncertainty on international demand (e.g., from China), U.S. growers and the distribution channel have continued to follow conservative procurement practices, buying goods closer to time-of-need and minimizing carrying costs The non-crop, Specialty products markets (e.g., big box stores, professional applicators) have followed a similar procurement pattern. Meanwhile, the Company’s international markets have softened due to weather conditions occasioned by El Niño. As a consequence, on a consolidated basis, the Company’s financial performance declined with respect to both net sales and profitability in the period. The fourth quarter has historically been an important period for the Company’s annual results. Based upon the magnitude of customer prepayments received in the aggregate in 2026 and recent sales-planning discussions with certain key customers, the Company anticipates that fourth quarter results may represent a meaningful portion of full-year performance. However, the timing and volume of customer purchases, pricing, weather conditions, and freight and raw material costs remain uncertain.

Overall net sales during the quarter declined by 9% over the comparable period last year. This performance included decreases in net sales of both U.S. Crop and U.S. Specialty (both down 2%) and International business (down 17%). With lower sales, gross profit decreased 23% quarter-over-quarter. Further, with increased freight costs, due primarily to an 80% increase in diesel cost, and higher raw material prices also driven by oil prices, partially offset by strong manufacturing performance, gross margin percentages ended at 24% for the third quarter of 2026, as compared to 29% in the same quarter of the prior year.

The Company reduced its operating expenses by 16% compared to the same quarter of the prior year, operating expenses as a percentage of net sales improved to 32% from 34% compared to the same quarter of the prior year. Research, product development and regulatory expenses declined by 6%, and general and administrative expenses declined by 12%, which was partially offset by an increase in selling expenses by 8%.

Interest expense, net, increased by $4,226 due to increased borrowing under the new debt structure and the comparatively higher effective interest rate (consisting of the First Lien Term Loan and Second Lien Term Loan), that was put into place on March 13, 2026.

19


Results of Operations

For the Three Months Ended September 30,

2026

2025

Change

% Change

Net sales:

U.S. Crop

$

42,316

$

43,310

$

(994

)

-2

%

U.S. Specialty

18,872

19,233

(361

)

-2

%

Total U.S.

61,188

62,543

(1,355

)

-2

%

International

47,188

56,770

(9,582

)

-17

%

Total net sales

$

108,376

$

119,313

$

(10,937

)

-9

%

Total cost of sales

$

(82,124

)

$

(85,099

)

$

2,975

-3

%

Total gross profit

$

26,252

$

34,214

$

(7,962

)

-23

%

Total gross margin

24

%

29

%

Our domestic Crop business recorded net sales during the third quarter of 2026 that were 2% lower than those of the third quarter of 2025. Performance across the portfolio was mixed. The decrease was driven largely by reduced demand for soil fumigants, the nematicide, Aztec® and the cotton insecticide, Bidrin®. These decreases were partially offset by stronger sales of our granular soil insecticide, Thimet®, our cotton defoliant, Folex®, and direct business-to-business sales from the U.S. Crop business to certain foreign customers (as part of our organization restructuring)

Our domestic Specialty business experienced a 2% decline in net sales over the third quarter. Overall, lower sales were driven primarily by a shift in inventory stocking dynamics affecting our turf and ornamental portfolio as well as reduced demand for insect growth regulators. These decreases were partially offset by stronger sales of our turf fungicide product and our mosquito adulticide, Naled®.

Net sales of our international businesses decreased by 17% during the period. This decline arose primarily from poor weather conditions in Mexico and Central American due to El Niño effect. In addition, certain direct business-to-business sales are now managed by the US crop business as part of our drive for improved operational efficiency. These decreases were partially offset by increased sales of soil fumigants and expansion of our business in Ecuador, where commercial operations are expanding.

On a consolidated basis, gross profit for the third quarter of 2026 decreased by 23% as compared to the third quarter of 2025, due largely to decreased sales volume, increased freight costs and raw material costs, partially offset by better manufacturing performance.

While operating expenses decreased on both an absolute level, $34,217 for the third quarter of 2026, compared to $40,719 for the third quarter of 2025; and as a percentage of net sales, 32% for the third quarter of 2026, compared to 34% for the third quarter of 2025, with lower gross profit, the Company recorded an operating loss of $7,965 for the third quarter of 2026, compared to $6,505 for the third quarter of 2025. Significantly higher net interest expense of $9,146 for the third quarter of 2026, compared to $4,920 for the third quarter of 2025, resulted in a net loss of $17,668 for the third quarter of 2026, compared to $12,358 for the third quarter of 2025.

20


The change in operating expenses by department is as follows:

For the Three Months Ended September 30,

2026

2025

Change

% Change

Operating expenses

Selling

$

12,023

$

11,142

$

881

8

%

General and administrative

Other

10,742

12,540

(1,798

)

-14

%

Amortization

3,032

3,065

(33

)

-1

%

Research, product development and regulatory

5,342

5,654

(312

)

-6

%

Product liability claims

22

7,029

(7,007

)

-100

%

CFO transition costs

1,316

—

1,316

100

%

Transformation

1,665

1,442

223

15

%

Asset impairments

—

93

(93

)

-100

%

Loss (gain) on sale of assets

75

(246

)

321

-130

%

Total

$

34,217

$

40,719

$

(6,502

)

-16

%

•

Selling expenses increased for the three months ended September 30, 2026, as compared to the same period of the prior year. This increase was primarily associated with an increase in advertising and promotion expenses.

•

Other general and administrative expenses decreased during the three months ended September 30, 2026, as compared to the same period of the prior year. The primary drivers were reduced bonus accruals coupled with lower stock based compensation expenses.

•

Amortization remained consistent during the three months ended September 30, 2026, as compared to the same period of the prior year.

•

Research, product development and regulatory expenses decreased for the three months ended September 30, 2026, as compared to the same period of the prior year. This decrease was driven by reduced expenses associated with product development.

•

Product liability claims relate to the Company’s Specialty business.

•

For the three months ended September 30, 2026, $1,316 related to severance and other costs associated with the CFO transition announced on October 1, 2026.

•

The following table shows the different components of transformation expenses for the three months ended September 30, 2026 and 2025:

For the Three Months Ended September 30,

2026

2025

Consulting and strategic advisory services

$

715

$

673

Other termination and retention costs

204

451

IT implementations

52

318

Plant reorganization costs

226

—

Other

468

—

Total

$

1,665

$

1,442

Transformation costs related to the Company’s digital and structural transformation project and manufacturing footprint optimization increased for the three months ended September 30, 2026, as compared to the same period of the prior year.

21


Average Indebtedness and Interest expense

Interest costs are summarized in the following table:

For the Three Months Ended September 30, 2026

For the Three Months Ended September 30, 2025

Average
Debt

Interest
Expense

Interest
Rate

Average
Debt

Interest
Expense

Interest
Rate

Average indebtedness

$

285,119

$

8,353

11.7

%

$

209,575

$

4,315

8.2

%

Amortization of deferred loan fees

—

1,120

—

—

597

—

Other interest income

—

(271

)

—

—

24

—

Subtotal

$

285,119

$

9,202

12.9

%

$

209,575

$

4,936

9.4

%

Capitalized interest

—

(56

)

—

—

(16

)

—

Total

$

285,119

$

9,146

12.8

%

$

209,575

$

4,920

9.4

%

The Company's borrowings in the three months ended September 30, 2026, were higher compared to the same period of the prior year, mainly as a result of the new debt structure put into place on March 13, 2026. The Company refinanced its revolving credit line with a term loan structure that resulted in an increase in the effective interest rate.

Income tax expense was $536 for the three months ended September 30, 2026, as compared to $422 for the three months ended September 30, 2025. The effective income tax rate for the three months ended September 30, 2026, was computed based on the estimated effective tax rate for the full year which is approximately 17%, excluding discrete items and entities subject to full valuation allowances against related net deferred tax assets. The Company continues to maintain valuation allowances established against the net deferred tax assets of the U.S. and certain international entities, primarily in Brazil, for the three months ended September 30, 2026. During the three months ended September 30, 2026, several of the Company’s international businesses outside of Brazil were profitable, resulting in an income tax expense.

Our overall net loss for the three months ended September 30, 2026 was $17,668 or ($0.61) per basic and diluted share, as compared to net loss of $12,358 or ($0.43) per basic and diluted share in the same quarter of 2025.

Nine Months Ended September 30, 2026 and 2025:

Overview of the Company’s Performance

The domestic crop protection market for the nine months ended September 30, 2026, was stable; channel inventories were low, and demand was generally consistent with seasonal need. First half performance of the Company’s Crop business was more resilient than that of the third quarter, as the farm economy continued to endure the more prolonged effects of higher fuel and fertilizer cost, cost of capital and market uncertainty. Similarly, the domestic Specialty market was strong through the first half of 2026 and declined slightly during the third quarter. By contrast, in the face of adverse weather and increased raw materials prices, the International markets were not as strong. On a consolidated basis, the Company’s net sales performance for the nine months ended September 30, 2026 was down modestly as compared to the same period during the prior year. The fourth quarter has historically been an important period for the Company’s annual results. Based upon the magnitude of customer prepayments received in the aggregate in 2026 and recent sales-planning discussions with certain key customers, the Company anticipates that fourth quarter results may represent a meaningful portion of full-year performance. However, the timing and volume of customer purchases, pricing, weather conditions, and freight and raw material costs remain uncertain.

The Company’s consolidated net sales for the nine months ended September 30, 2026 declined by 4%, as compared to the same period of the prior year. This performance included U.S. Crop sales that were up 3%, U.S. Specialty net sales up 6%, and International net sales down 14%. Gross profit declined by 5% and the gross margin percentage ended at 29% for both the nine months ended September 30, 2026 and the same period of the prior year.

The Company reduced its operating expenses by approximately 5% and, when expressed as a percentage of net sales, improved to 30% compared to 31% during the same period a year ago. Within operating expenses, selling expenses increased by 1%, general and administrative expenses decreased by approximately 4%, and research, product development and regulatory expenses were flat.

Interest expense, net, increased $10,931 due to increased borrowing and the comparatively higher effective interest rate under the new debt structure (consisting of the First Lien Term Loan and Second Lien Term Loan), that was put into place on March 13, 2026.

22


Results of Operations

For the Nine Months Ended September 30,

2026

2025

Change

% Change

Net sales:

U.S. Crop

$

157,510

$

153,511

$

3,999

3

%

U.S. Specialty

57,045

54,067

2,978

6

%

Total U.S.

214,555

207,578

6,977

3

%

International

134,143

156,848

(22,705

)

-14

%

Total net sales

$

348,698

$

364,426

$

(15,728

)

-4

%

Total cost of sales

$

(249,316

)

$

(259,474

)

$

10,158

-4

%

Total gross profit

$

99,382

$

104,952

$

(5,570

)

-5

%

Total gross margin

29

%

29

%

Our domestic crop business recorded net sales during the nine months ended September 30, 2026 that were 3% higher than those of the comparable period of 2025, due to improved industry demand for the Company’s Impact herbicide, soil insecticides Thimet and Mocap and, to a lesser extent, the Company’s biologicals portfolio. These increases were partially offset by declines in sales of our Bidrin cotton insecticide, Counter nematicide, Aztec corn soil insecticide, and soil fumigants and as the result of certain direct business-to-business sales that are now managed by the U.S. Crop business as part of our drive for improved operational efficiency.

Our domestic Specialty business posted a 6% increase in net sales in the nine months ended September 30, 2026, as compared to the same period of 2025, driven by continued strong demand for our Naled mosquito adulticide and other Specialty products.

Net sales of our international businesses decreased by 14% during the nine months ended September 30, 2026, as compared to the same period of 2025. Poor weather conditions in Central America slowed sales in the nine-month period. In addition, certain direct business-to-business sales are now managed by the U.S. crop business as part of our drive for improved operational efficiency. These decreases were partially offset by improved sales in Ecuador, arising from the Company’s launch of Mocap for use on bananas, as well as in Australia, with the registration of our fungicide on cereals. In addition, certain direct business-to-business sales are now managed by the US crop business as part of our drive for improved operational efficiency.

On a consolidated basis, gross profit for the nine months ended September 30, 2026 declined by 5%, as compared to the same period of the prior year. Gross margin for the nine months ended September 30, 2026 was flat at 29%, as compared to the same period of the prior year.

23


The change in operating expenses by department is as follows:

For the Nine Months Ended September 30,

2026

2025

Change

% Change

Operating expenses

Selling

$

33,711

$

33,498

$

213

1

%

General and administrative

Other

37,236

39,320

(2,084

)

-5

%

Amortization

9,094

9,180

(86

)

-1

%

Legal reserves

92

—

92

100

%

Research, product development and regulatory

17,097

17,139

(42

)

-

%

Product liability claims

223

7,029

(6,806

)

-97

%

CFO transition costs

1,316

—

1,316

100

%

Transformation

5,975

5,254

721

14

%

Asset impairments

943

227

716

315

%

Loss (gain) on sale of assets

75

(246

)

321

-130

%

Total

$

105,762

$

111,401

$

(5,639

)

-5

%

•

Selling expenses remained consistent during the nine months ended September 30, 2026, as compared to the same period of the prior year.

•

Other general and administrative expenses declined during the nine months ended September 30, 2026, as compared to the same period of the prior year. The primary drivers were reduced bonus accruals and lower stock-based compensation expenses, partially offset by an increase in salary expenses.

•

Amortization remained consistent during the nine months ended September 30, 2026, as compared to the same period of the prior year.

•

Research, product development and regulatory expenses remained consistent during the nine months ended September 30, 2026, as compared to the same period of the prior year.

•

Product liability claims relate to the Company’s Specialty business.

•

For the nine months ended September 30, 2026, $1,316 related to severance and other costs associated with the CFO transition announced on October 1, 2026.

•

Asset impairments for the nine months ended September 30, 2026, relate to the decision to discontinue synthesis operations at the Los Angeles manufacturing facility.

•

The following table shows the different components of transformation expenses for the nine months ended September 30, 2026 and 2025:

For the Nine Months Ended September 30,

2026

2025

Consulting and strategic advisory services

$

802

$

1,822

Other termination and retention costs

1,081

1,618

Transformation related employee costs

63

—

IT implementations

60

1,011

Plant reorganization costs

3,341

—

Legal and regulatory expense

—

711

Other

628

92

Total

$

5,975

$

5,254

Transformation costs related to the Company’s digital and structural transformation project and manufacturing footprint optimization increased during the nine months ended September 30, 2026, as compared to the same period of the prior year. The Company expects that these costs will decrease over time.

24


Average Indebtedness and Interest expense

Interest costs are summarized in the following table:

For the Nine Months Ended September 30, 2026

For the Nine Months Ended September 30, 2025

Average
Debt

Interest
Expense

Interest
Rate

Average
Debt

Interest
Expense

Interest
Rate

Average indebtedness

$

261,293

$

21,737

11.1

%

$

197,097

$

11,974

8.1

%

Amortization of deferred loan fees

—

2,899

—

—

1,167

—

Other interest income

—

(427

)

—

—

39

—

Subtotal

$

261,293

$

24,209

12.4

%

$

197,097

$

13,180

8.9

%

Capitalized interest

—

(143

)

—

—

(45

)

—

Total

$

261,293

$

24,066

12.3

%

$

197,097

$

13,135

8.9

%

The Company’s borrowings during the nine months ended September 30, 2026 were higher when compared to the same period of the prior year, mainly as a result of the new debt structure put into place on March 13, 2026. The Company refinanced its revolving credit line with a term loan structure that resulted in an increase in the effective interest rate.

Income tax expense was $1,043 for the nine months ended September 30, 2026, as compared to $1,574 for the nine months ended September 30, 2025. The effective income tax rate for the nine months ended September 30, 2026 was computed based on the estimated effective tax rate for the full year which is approximately 17%, excluding discrete items and entities subject to full valuation allowances against related net deferred tax assets. The Company continues to maintain valuation allowances established against the net deferred tax assets of the U.S. and certain international entities, primarily in Brazil, for the nine months ended September 30, 2026. During the nine months ended September 30, 2026, several of the Company’s international businesses outside of Brazil were profitable, resulting in an income tax expense.

Our overall net loss for the nine months ended September 30, 2026 was $31,682 or ($1.10) per basic and diluted share, as compared to net loss of $21,669 or ($0.76) per basic and diluted share in the nine months ended September 30, 2025.

Liquidity and Capital Resources

The following table presents selected data from our condensed consolidated statements of cash flows for the periods presented:

For the Nine Months Ended September 30,

2026

2025

Net cash used in operating activities

$

(12,346

)

$

(27,144

)

Net cash used in investing activities

(9,815

)

(2,042

)

Net cash provided by financing activities

93,669

32,062

Net increase in cash

71,508

2,876

Effect of exchange rate changes on cash and cash equivalents

(24

)

1,405

Cash at beginning of period

12,425

12,514

Cash at end of period

$

83,909

$

16,795

The Company used cash of $12,346 in operating activities during the nine months ended September 30, 2026, as compared to $27,144 during the nine months ended September 30, 2025. Included in the $12,346 are net loss of $31,682, plus non-cash depreciation, amortization of intangibles and other assets in the amount of $13,447, provision for bad debts in the amount of $2,469, stock compensation in the amount of $901 and amortization of deferred loan fees in the amount of $2,899. Also included are a net change in deferred income taxes of $1,073, and change in liabilities for uncertain tax positions or unrecognized tax benefits of $127 and changes in lease obligations and non-cash lease expense in the amount of $120. These together resulted in a cash outflow of $10,571, as compared to an outflow of $4,031 for the same period of 2025.

During the nine months ended September 30, 2026, the Company increased net working capital by $60,093, as compared to an increase of $29,758 during the same period of the prior year. The biggest driver of the increase was the restructuring of the Company’s debt which resulted in a cash inflow of $68,419 which is included in the change in working capital. In addition, accounts receivable decreased by $14,812, as compared to a decrease by $935 in the same period of 2025. This change was mainly driven by lower sales and a shift to net pricing in 2026 compared to 2025. Inventories increased by $16,007, as compared to an increase of $16,513 during

25


the same period of 2025. Customer prepayments increased by $11,527, as compared to a decrease of $21,453 in the same period of 2025, driven by customers’ decisions regarding the amount of prepayments they made in 2026 compared to the same period of 2025. Accrued program costs decreased by $5,454, as compared to an increase of $12,285 in the prior year, as a result of timing of customers purchases, program simplification, and the mix of sales. Our accounts payable balances decreased by $960, as compared to an increase of $11,859 in the same period of 2025. Prepaid expenses and other assets increased by $1,039, as compared to an increase of $965 in the same period of 2025. Income tax receivable and payable, net changed by $3,526 as compared to $1,083 in the prior year. Finally, other payables and accrued expenses decreased by $8,180, as compared to a decrease of $8,178 in the prior year.

With regard to our program accrual, the increase primarily reflects our initiatives to simplify customer programs, and as a result of the level and mix of sales and customers in the nine months ended September 30, 2026, as compared to the prior year. The Company accrues programs in line with the growing season upon which specific products are targeted. Typically crop products have a growing season that ends on September 30th of each year. During the nine months ended September 30, 2026, the Company made accruals for programs in the amount of $27,742 and made payments in the amount of $32,644. During the comparable period of the prior year, the Company made accruals in the amount of $52,852 and payments in the amount of $40,567.

Cash used for investing activities was $9,815 for the nine months ended September 30, 2026, as compared to $2,042 for the nine months ended September 30, 2025. The Company spent $4,676 on fixed assets purchases primarily focused on its manufacturing infrastructure.

During the nine months ended September 30, 2026, financing activities provided $93,669, as compared to $32,062 during the same period of the prior year. Net borrowings under the Company's debt structure amounted to $109,875 during the nine months ended September 30, 2026, as compared to $34,919 during the same period of the prior year. As previously noted, this was driven by the retirement of the pre-existing revolving line of credit and replacement by two term loans. The Company made payments in the amount of $16,581 relating to loan fees. Lastly, in exchange for shares of common stock returned by employees, we paid $99 and $147 for tax withholdings on stock-based compensation awards during the nine months ended September 30, 2026 and 2025, respectively.

As of September 30, 2026 our debt structure includes two term loans. As of December 31, 2025, our debt structure included a senior credit facility. The debt structure is summarized in the following table:

Long-term indebtedness

September 30, 2026

December 31, 2025

Current portion of long-term debt

$

3,750

$

—

Long-term debt, net of current portion

281,288

174,000

Unamortized debt discount and debt issuance costs

(17,351

)

(3,015

)

Total indebtedness

$

267,687

$

170,985

As of September 30, 2026, the Company was in compliance with its financial covenants.

We believe that anticipated cash flow from operations and existing cash balances will be sufficient to provide us with liquidity necessary to fund our working capital and cash requirements for the next twelve months. The Company’s ability to remain in compliance with the leverage covenant under its First Lien Term Loan depends on generating significant adjusted EBITDA during the fourth quarter of 2026.

Recently Issued Accounting Guidance

Please refer to Note 1 in the accompanying Notes to the Condensed Consolidated Financial Statements for recently issued and adopted accounting standards.

Critical Accounting Policies and Estimates

The Company continually re-assesses the critical accounting policies used in preparing its financial statements. In the Company’s Form 10-K filed with the SEC for the year ended December 31, 2025, the Company provided a comprehensive statement of critical accounting policies. These policies have been reviewed in detail as part of the preparation work for this Form 10-Q. After our review of these matters, we have determined that, during the subject reporting period there has been no material change to the critical accounting policies that are listed in the Company’s Form 10-K for the year ended December 31, 2025.

26


Item 3. Quantitative and Qualitative Disclosures About Market Risk

The Company is primarily exposed to changes in interest rates related to its borrowing activities. The Company’s indebtedness to its primary lenders is evidenced by two term loans with variable rates of interest, which fluctuate with changes in the lenders' reference rate (SOFR). An increase or decrease in interest rates by 25 bps would impact the Company’s net loss by approximately $712 based on the Company’s currently outstanding principal balance of approximately $285,000.

The Company faces market risk to the extent that changes in foreign currency exchange rates affect our non-U.S. dollar functional currency as to foreign subsidiaries’ revenues, expenses, assets and liabilities. The Company currently does not engage in hedging activities with respect to such exchange rate risks.

Assets and liabilities outside the U.S. are located in regions where the Company has subsidiaries or joint ventures: Central America, South America, North America, Europe, Asia, and Australia. The Company’s investments in foreign subsidiaries and joint ventures with a functional currency other than the U.S. dollar are generally considered long-term. Accordingly, the Company does not hedge these net investments.

For more information, please refer to the applicable disclosures in the Company’s Form 10-K filed with the SEC for the year ended December 31, 2025.

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

As of September 30, 2026, the Company has a comprehensive set of disclosure controls and procedures designed to ensure that all information required to be disclosed in our filings under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to the Company’s management, including its Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosures. As of September 30, 2026, the Company’s management, including the Company’s Chief Executive Officer and Chief Financial Officer, has concluded, based on their evaluation, that the Company’s disclosure controls and procedures are effective to provide reasonable assurance of the achievement of the objectives described above. There were no changes in the Company’s internal controls over financial reporting that occurred during the most recent quarter that have materially affected, or are reasonably likely to materially affect, the Company’s internal controls over financial reporting.

27


Part II. Other Information

The Company was not required to report any matters or changes for any items of Part II except as disclosed below.

Item 1. Legal Proceedings

Please refer to Note 12 in the accompanying Notes to the Condensed Consolidated Financial Statements for legal updates.

Item 1A. Risk Factors

The Company continually re-assesses the business risks, and as part of that process detailed a range of risk factors in the disclosures in American Vanguard’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed on March 16, 2026. There have been no material changes in our risk factors as of September 30, 2026, except as follows:

Continued military activity in the Middle East has significantly increased fuel and freight costs domestically. The interruption of shipping lanes and the attendant interference with the supply of oil from the Middle East arising from regional military activity has significantly increased fuel prices and, consequentially, freight costs for the Company particularly with respect to liquid products that are shipped in bulk. These increases have eroded the Company’s profit margin in a number of products. There is no guarantee that the geopolitical situation giving rise to these increased costs will end any time soon. Nor is there any guarantee that the Company, through price increases or other measures, will be able to return to higher profit margins for these products. In short, it is possible that, if these conditions persist, the Company’s earnings could continue to be adversely affected.

The development of Agentic AI tools may overtake the efficacy of available cybersecurity defense tools and, as such, could put the Company’s computing systems at risk. Fueled by enormous investment and activity from competing global developers, agentic AI solutions are evolving at a rapid pace and becoming increasingly powerful. By contrast, cybersecurity defense tools are evolving at a slower rate and are largely configured to defend against traditional, pre-agentic AI threats. Thus, it is possible that the strength of existing defense tools will soon be exceeded by that of new, agentic AI tools. While the Company is taking extensive measures to ensure that its computing systems are well-defended, there is no guarantee that agentic AI tools, whether on their own or in the hands of threat actors, will not breach these systems, which, in turn, could have a material adverse effect upon the Company’s operations or financial performance.

The Company’s primary synthesis factories are dependent upon the continued provision of shared services from competitors. The Company’s manufacturing facilities in both Hannibal, Missouri and Axis, Alabama depend upon the provision of essential services (e.g., utilities, waste treatment) from competitors that are co-located with the Company on those sites. Further, while it owns the machinery and equipment at those sites, the Company is a tenant, and the competitors are landlords, as per the terms of ground leases. There is no guarantee that the landlords of either site will continue to be able to supply some or all shared services to the Company without interruption. Nor does the Company have any control over the disposition of the fee interest of the sites on which its operations are situated. Cessation of some or all shared services by the landlords without sufficient lead time could have a material adverse effect upon the Company’s ability to produce various high-margin products.

The Company’s ability to remain in compliance with the leverage covenant under its 1L Term Loan depends on generating significant adjusted EBITDA during the fourth quarter of 2026. Historically, the fourth quarter has been an important period for the Company’s annual results. In light of the Company’s financial performance through the first nine months of 2026, remaining in compliance with this covenant will require the Company to generate significant adjusted EBITDA during the fourth quarter. There can be no assurance that the Company will generate adjusted EBITDA sufficient to remain in compliance with this covenant. Further, any noncompliance under the 1L Term Loan could have a material adverse effect on the Company’s liquidity, financial condition and results of operations.

If we fail to satisfy the continued listing standards of the New York Stock Exchange, our Common Stock could be delisted. Our Common Stock is listed on the New York Stock Exchange under the symbol “AVD.” To maintain that listing, we must satisfy the NYSE’s continued listing standards, which include, among other things, a minimum average closing share price. The market price of our Common Stock may be affected by, among other things, our recent net losses, significant leverage and weakness in the agricultural economy. If we fail to satisfy any of the listing standards, the NYSE could begin suspension and delisting procedures. A delisting could reduce the liquidity and market price of our Common Stock, impair our ability to raise equity capital and adversely affect our reputation with customers, suppliers and employees. Any of these could adversely affect our business and the value of our Common Stock.

Item 2. Purchases of Equity Securities by the Issuer

Under the First Lien Term Loan, the Company is restricted in its ability to make stock repurchases.

28


Item 6. Exhibits

Exhibits required to be filed by Item 601 of Regulation S-K:

Exhibit

No.

Description

10.1*†

Offer Letter from American Vanguard Corporation to Matthew Horwath, dated as of September 21, 2026.

10.2*†

Transition Agreement by and between American Vanguard Corporation and David T. Johnson, dated as of October 1, 2026.

31.1

Certification of Chief Executive Officer Pursuant to Section 302 of The Sarbanes-Oxley Act of 2002.

31.2

Certification of Chief Financial Officer Pursuant to Section 302 of The Sarbanes-Oxley Act of 2002.

32.1

Certification Pursuant to Section 906 of The Sarbanes-Oxley Act of 2002.

101

The following materials from American Vanguard Corp’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2026, formatted in iXBRL (Inline Extensible Business Reporting Language): (i) Condensed Consolidated Statements of Operations; (ii) Condensed Consolidated Statements of Comprehensive Income; (iii) Condensed Consolidated Balance Sheets; (iv) Condensed Consolidated Statement of Stockholders’ Equity; (v) Condensed Consolidated Statements of Cash Flows; and (vi) Notes to Condensed Consolidated Financial Statements, tagged as blocks of text.

104

The cover page from the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2026, has been formatted in Inline XBRL.

*

Filed herewith.

†

Indicates a management contract or compensatory plan.

29


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

american vanguard corporation

Dated: November 9, 2026

By:

/s/ DOUGLAS A. KAYE III

Douglas A. Kaye III

Chief Executive Officer

Dated: November 9, 2026

By:

/s/ MATTHEW HORWATH

Matthew Horwath

Chief Financial Officer (Principal Financial Officer)

Dated: November 9, 2026

By:

/s/ DAVID T. JOHNSON

David T. Johnson

Chief Accounting Officer (Principal Accounting Officer)

30


来源:SEC EDGAR · 本站存档